Janssens W J, Van de Water A, Xhonneux R, Reneman R S, Van Nueten J M, Janssen P A
Department of Cardiovascular Pharmacology, Janssen Research Foundation, Beerse, Belgium.
Eur J Pharmacol. 1989 Jan 2;159(1):89-95. doi: 10.1016/0014-2999(89)90047-2.
Nebivolol is a chemically novel, potent and selective beta 1-adrenoceptor-blocking agent that acutely lowers arterial blood pressure in hypertensive patients and rats without depressing, or even enhancing, left ventricular function. These properties could be compatible with a partial agonistic effect of beta-adrenoceptor-blocking agents. It was the aim of the present study to investigate whether nebivolol has intrinsic sympathomimetic properties. The study was performed on reserpinized dogs and spontaneously hypertensive rats, and on various isolated tissues from various species. Unlike pindolol and practolol, nebivolol did not exert a stimulating effect on the heart rate and left ventricular function in reserpinized animals and/or in isolated atria of reserpinized rats at doses that are clinically active. Nebivolol did not induce relaxation of isolated coronary arteries and saphenous veins at concentrations that block beta-adrenoceptors. These findings indicate that nebivolol is devoid of intrinsic sympathomimetic activity at clinically relevant doses.
奈必洛尔是一种化学结构新颖、强效且具有选择性的β1肾上腺素能受体阻滞剂,可在不抑制甚至增强左心室功能的情况下,迅速降低高血压患者和大鼠的动脉血压。这些特性可能与β肾上腺素能受体阻滞剂的部分激动效应相符。本研究的目的是调查奈必洛尔是否具有内在拟交感活性。该研究在利血平化的犬和自发性高血压大鼠以及来自不同物种的各种离体组织上进行。与吲哚洛尔和普拉洛尔不同,在临床有效剂量下,奈必洛尔对利血平化动物和/或利血平化大鼠的离体心房的心率和左心室功能没有刺激作用。在阻断β肾上腺素能受体的浓度下,奈必洛尔不会引起离体冠状动脉和隐静脉的舒张。这些发现表明,在临床相关剂量下,奈必洛尔没有内在拟交感活性。